logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2018—Lenalidomide plus rituximab may be a first-line option for untreated follicular lymphoma

The current standard of care is rituximab + chemotherapy, followed by maintenance rituximab.